Study limitation: Durvalumab (brand: Imfinzi) is inferred as the consolidation immunotherapy agent in the HARVARD-DURVA cohort based on cohort naming; the abstract does not explicitly name the drug | ReachRx
Thymic radiation is associated with worse outcomes in patients with NSCLC
Study limitation reported by the research below: “Durvalumab (brand: Imfinzi) is inferred as the consolidation immunotherapy agent in the HARVARD-DURVA cohort based on cohort naming; the abstract does not explicitly name the drug.”
